share_log

Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)

Brokers Offer Predictions for Avivagen Inc.'s FY2024 Earnings (OTCMKTS:VIVXF)

经纪商提供对英杰华公司2024财年收益的预测(场外交易代码:VIVXF)
Defense World ·  2022/09/02 01:51

Avivagen Inc. (OTCMKTS:VIVXF – Get Rating) – Investment analysts at Zacks Small Cap issued their FY2024 earnings per share (EPS) estimates for Avivagen in a note issued to investors on Wednesday, August 31st. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($0.02) per share for the year. The consensus estimate for Avivagen's current full-year earnings is ($0.07) per share.

Avivagen Inc.(OTCMKTS:VIVXF-GET Rating)-Zack Small Cap的投资分析师在8月31日星期三发布的一份给投资者的报告中发布了他们对Avivagen 2024财年每股收益(EPS)的估计。Zack Small Cap分析师D·鲍兹预计,该公司今年的每股收益将达到0.02美元。对英杰华目前全年收益的普遍预期为每股0.07美元。

Get
到达
Avivagen
英杰华
alerts:
警报:

Avivagen Stock Performance

英杰华汽车的股票表现

Shares of VIVXF opened at $0.13 on Thursday. The company has a market capitalization of $9.33 million, a price-to-earnings ratio of -1.40 and a beta of 0.13. The stock has a 50 day moving average of $0.14 and a 200 day moving average of $0.15. Avivagen has a 12 month low of $0.12 and a 12 month high of $0.38.

周四,VIVXF的股价开盘报0.13美元。该公司市值为933万美元,市盈率为-1.40倍,贝塔系数为0.13。该股的50日移动均线切入位为0.14美元,200日移动均线切入位为0.15美元。Avivagen的12个月低点为0.12美元,12个月高位为0.38美元。

Avivagen (OTCMKTS:VIVXF – Get Rating) last issued its quarterly earnings results on Wednesday, June 15th. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02). The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.23 million.
Avivagen(OTCMKTS:VIVXF-GET Rating)最近一次发布季度收益报告是在6月15日星期三。该公司公布该季度每股收益为0.02美元,符合分析师一致预期的0.02美元。该业务当季营收为70万美元,高于分析师预期的23万美元。

About Avivagen

关于英杰华

(Get Rating)

(获取评级)

Avivagen Inc, a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr.

Avivagen Inc是一家生命科学公司,专注于开发家畜饲料产品并将其商业化,这些产品支持免疫功能,帮助动物实现生长和生产力。该公司提供OXC-beta牲畜,这是一种预混料,用于牲畜饲料;

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Avivagen (VIVXF)
  • Could Nike Stock be Oversold, but Still Overvalued?
  • Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
  • Will Royal Caribbean's Broadband Partnership Drive Revenue?
  • Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
  • DocuSign Has Important Issues to Address When it Reports Earnings
  • 免费获取StockNews.com关于Avivagen的研究报告(VIVXF)
  • 耐克股票会被超卖,但仍被高估吗?
  • 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗?
  • 皇家加勒比的宽带合作能否推动收入增长?
  • 芯片设备制造商Entigis很有潜力,但它现在可以买下吗?
  • DocuSign在报告收益时有重要的问题需要解决

Receive News & Ratings for Avivagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avivagen and related companies with MarketBeat.com's FREE daily email newsletter.

接受Avivagen Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Avivagen和相关公司的最新新闻和分析师评级的每日简明摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发